Feature | SCAI | May 14, 2018

SCAI 2018 Late-breaking Clinical Trials

Richard Schatz, M.D., (center) is research director of cardiovascular interventions at the Heart, Lung, and Vascular Center at Scripps Clinic, speaking at a SCAI session on collaboration with industry to bring new device technologies to market. He is best known as the co-inventor of the first coronary stent, the Palmaz-Schatz stent. Left is Ziyad Hijazi, M.D., MPH, director of the Sidra Cardiac Program. #SCAI, #SCAI2018

Richard Schatz, M.D., (center) research director of cardiovascular interventions at the Heart, Lung, and Vascular Center at Scripps Clinic, speaking at a 2018 SCAI session on collaboration with industry to bring new device technologies to market. He is best known as the co-inventor of the first coronary stent, the Palmaz-Schatz stent. Left is Ziyad Hijazi, M.D., MPH, director of the Sidra Cardiac Program, Sidra Medical and Research Center, Doha, Qatar, who has been active in new device technologies for structural heart disease.


Here is an aggregation of all the news and late-breaking studies presented at the 2018 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions. 

 

Late-breaking Studies:

Derivation of a Simple Risk Tool to Predict 30-day Readmissions after Transcatheter Aortic Valve Replacement — Presented by Sahil Khera, M.D., Massachusetts General Hospital

Procedural, Clinical and Health Status Outcomes in Chronic Total Coronary Occlusion Revascularization with Zotarolimus-Eluting Stents: Results from the PERSPECTIVE Trial — Presented by David Kandzari, M.D., Piedmont Heart Institute

Length of Stay Post Trans-Femoral Transcatheter Aortic Valve Replacement — Presented by Siddharth Wayangankar, M.D., Shands/University of Florida

A Prospective, Single-Arm Multicenter Trial of Catheter-Directed Mechanical Thrombectomy for Intermediate-Risk Acute Pulmonary Embolism: The FLARE Study — Presented by Thomas Tu, M.D., Baptist Health Louisville

Immunomodulatory Therapy Reduces Atherosclerotic Plaque Burden by Coronary Computed Tomography Angiography in Psoriasis at One-Year — Presented by Nehal Mehta, M.D., National Heart, Lung, and Blood Institute

Culprit Vessel vs. Multivessel Revascularization Strategies in Acute Myocardial Infarction and Cardiogenic Shock: Insights from the British Columbia Cardiac Registry — Presented by Bilal Iqbal, M.D., Victoria Heart Institute Foundation, Canada

PROGRESS-CTO: The Hybrid Approach of Percutaneous Coronary Interventions for Chronic Total Occlusions — Presented by Peter Tajti, M.D., Abbott Northwestern Hospital

• The Abbott Post-Approval Study 1 MitraClip Registry: 1-year Results of the First 2,000 Patients in the Transcatheter Valve Therapy Registry — Presented by James Hermiller, M.D., The St. Vincent Medical Group at The Heart Center

Strategies to Reduce Acute Kidney Injury and Improve Clinical Outcomes After Percutaneous Coronary Intervention (PCI): A PRESERVE Trial Subgroup Analysis of the Prevention of Serious Adverse Events — Presented by Santiago Garcia, M.D., Minneapolis VA Medical Center

Discrepancy Between Physician Perception and Objective Assessment of Stroke, Stent Thrombosis and Bleeding Risk in Patients with Atrial Fibrillation Undergoing PCI: Results From the Aviator 2 International Registry — Presented by Roxana Mehran, M.D., Icahn School of Medicine at Mount Sinai

 

Other Key Presentations at SCAI:

More Patients Admitted With Cardiac Conditions in Winter Than Other Months

Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs

3-D Printed Models to Guide TAVR Improve Outcomes

SCAI Launches Diagnosis and Treatment Toolkit for Peripheral Artery Disease

Medtronic Shares Two-Year Harmony Transcatheter Pulmonary Valve Results

SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention

SCAI Releases Consensus Guidelines for Femoral-Popliteal Arterial Interventional Device Selection

Follow other SCAI news

 

 

Other Late-breaking Cardiology Trials in 2018:

ACC 2018 Late-Breaking Trials

TCT 2018 Late-breaking Cardiovascular Clinical Trials

EuroPCR 2018 Late-breaking Trials in Interventional Cardiology

Heart Rhythm 2018 Late-breaking Studies

 

 

#SCAI2018  #SCAI18  #SCAI


Related Content

News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — A programming algorithm, being tested by HonorHealth Research Institute for those patients with new or ...

Home June 20, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home June 12, 2024
Home
News | Cardiovascular Clinical Studies

June 6, 2024 —Cleveland Clinic researchers found higher amounts of the sugar alcohol xylitol are associated with ...

Home June 06, 2024
Home
Subscribe Now